Malaysia · Delayed Price · Currency is MYR Duopharma Biotech Berhad Statistics
Total Valuation
KLSE:DPHARMA has a market cap or net worth of MYR 1.29 billion. The enterprise value is 1.49 billion.
| Market Cap | 1.29B |
| Enterprise Value | 1.49B |
Important Dates
The last earnings date was Thursday, February 19, 2026.
| Earnings Date | Feb 19, 2026 |
| Ex-Dividend Date | Mar 12, 2026 |
Share Statistics
KLSE:DPHARMA has 961.94 million shares outstanding.
| Current Share Class | 961.94M |
| Shares Outstanding | 961.94M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 72.83% |
| Float | 450.08M |
Valuation Ratios
The trailing PE ratio is 14.74 and the forward PE ratio is 12.76. KLSE:DPHARMA's PEG ratio is 0.35.
| PE Ratio | 14.74 |
| Forward PE | 12.76 |
| PS Ratio | 1.38 |
| PB Ratio | 1.70 |
| P/TBV Ratio | 1.79 |
| P/FCF Ratio | 16.10 |
| P/OCF Ratio | 12.06 |
| PEG Ratio | 0.35 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.33, with an EV/FCF ratio of 18.65.
| EV / Earnings | 17.08 |
| EV / Sales | 1.60 |
| EV / EBITDA | 8.33 |
| EV / EBIT | 11.17 |
| EV / FCF | 18.65 |
Financial Position
The company has a current ratio of 2.61, with a Debt / Equity ratio of 0.65.
| Current Ratio | 2.61 |
| Quick Ratio | 1.68 |
| Debt / Equity | 0.65 |
| Debt / EBITDA | 2.76 |
| Debt / FCF | 6.19 |
| Interest Coverage | 5.41 |
Financial Efficiency
Return on equity (ROE) is 11.93% and return on invested capital (ROIC) is 10.54%.
| Return on Equity (ROE) | 11.93% |
| Return on Assets (ROA) | 5.92% |
| Return on Invested Capital (ROIC) | 10.54% |
| Return on Capital Employed (ROCE) | 11.79% |
| Weighted Average Cost of Capital (WACC) | 5.64% |
| Revenue Per Employee | 476,082 |
| Profits Per Employee | 44,692 |
| Employee Count | 1,957 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 2.10 |
Taxes
In the past 12 months, KLSE:DPHARMA has paid 27.45 million in taxes.
| Income Tax | 27.45M |
| Effective Tax Rate | 23.88% |
Stock Price Statistics
The stock price has increased by +12.61% in the last 52 weeks. The beta is 0.38, so KLSE:DPHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | +12.61% |
| 50-Day Moving Average | 1.38 |
| 200-Day Moving Average | 1.33 |
| Relative Strength Index (RSI) | 40.73 |
| Average Volume (20 Days) | 1,365,330 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:DPHARMA had revenue of MYR 931.69 million and earned 87.46 million in profits. Earnings per share was 0.09.
| Revenue | 931.69M |
| Gross Profit | 363.14M |
| Operating Income | 133.79M |
| Pretax Income | 114.91M |
| Net Income | 87.46M |
| EBITDA | 179.41M |
| EBIT | 133.79M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 290.87 million in cash and 495.72 million in debt, with a net cash position of -204.85 million or -0.21 per share.
| Cash & Cash Equivalents | 290.87M |
| Total Debt | 495.72M |
| Net Cash | -204.85M |
| Net Cash Per Share | -0.21 |
| Equity (Book Value) | 757.62M |
| Book Value Per Share | 0.79 |
| Working Capital | 505.45M |
Cash Flow
In the last 12 months, operating cash flow was 106.84 million and capital expenditures -26.76 million, giving a free cash flow of 80.08 million.
| Operating Cash Flow | 106.84M |
| Capital Expenditures | -26.76M |
| Free Cash Flow | 80.08M |
| FCF Per Share | 0.08 |
Margins
Gross margin is 38.98%, with operating and profit margins of 14.36% and 9.39%.
| Gross Margin | 38.98% |
| Operating Margin | 14.36% |
| Pretax Margin | 12.33% |
| Profit Margin | 9.39% |
| EBITDA Margin | 19.26% |
| EBIT Margin | 14.36% |
| FCF Margin | 8.60% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 3.40%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 3.40% |
| Dividend Growth (YoY) | 51.67% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 38.49% |
| Buyback Yield | n/a |
| Shareholder Yield | 3.40% |
| Earnings Yield | 6.79% |
| FCF Yield | 6.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.
| Last Split Date | Sep 6, 2021 |
| Split Type | Forward |
| Split Ratio | 1.3333333333 |
Scores
KLSE:DPHARMA has an Altman Z-Score of 2.83 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.83 |
| Piotroski F-Score | 7 |